Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma

Abstract

Increased DPP4 expression is associated with cellular invasion and more aggressive disease in papillary thyroid cancer. Targeting DPP4 may be a therapeutic strategy for DPP4-expressing thyroid cancer.

Is papillary thyroid microcarcinoma a biologically different disease? A propensity score‐matched analysis

“…This is in keeping with the experimental evidence that TGFBR2 overexpression may reduce tumorigenicity and metastatic potential of thyroid follicular cells . Targeting transforming growth factor‐β signaling has emerged as a topic of great interest in the management of thyroid cancer …”

Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation

“…In addition to MYC‐dependent and independent cell proliferation, transforming growth factor‐β may modulate telomerase activity of thyroid cancer cells . The transforming growth factor‐β signaling pathway is known to play an important role in cellular migration/invasion of PTC . Overall, aberrant growth due to senescence resistance as well as enhanced metastatic capacity may collaboratively confer an unfavorable prognosis in patients with TERT promoter mutations.…”

Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study

“…Importantly, the combination of metformin with sitagliptin showed a greater reduction in the number of metastatic lung nodules than treatment with metformin or sitagliptin alone . In the mouse xenograft model with papillary thyroid cancer, sitagliptin use was associated with reduced tumor growth, with the transforming growth factor‐β signaling pathway being potentially involved . In contradiction to these findings, Wang et al demonstrated in an in‐vivo study that use of DPP4 inhibitors increased the risk of metastasis in colon, hepatic, lung, ovary, and melanoma cell lines.…”

“…It plays an important role in tumor biology by acting as a tumor suppressor or activator depending upon the level of expression and its interaction with the microenvironment and selected chemokines . In animal models, DPP4/CD26 expression has been shown to be of prognostic value and is a potential therapeutic target in various malignancies . Of note is that the first phase I clinical trial involving CD26‐expressing cancers with an anti‐CD26 monoclonal antibody was recently completed and reported prolonged disease stabilization in patients with mesothelioma with good drug tolerance …”

“…[1][2][3] In animal models, DPP4/CD26 expression has been shown to be of prognostic value and is a potential therapeutic target in various malignancies. [4][5][6][7] Of note is that the first phase I clinical trial involving CD26-expressing cancers with an anti-CD26 monoclonal antibody was recently completed and reported prolonged disease stabilization in patients with mesothelioma with good drug tolerance. 8 Barreira da Silva et al 9 showed that in mice models with melanoma, DPP4 inhibition preserved the active form of chemokine CXCL10 which recruits T cells in tumor parenchyma.…”